Intervention

Rociletinib

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 7 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials7

Recruiting0

Common conditions4

Lead sponsors shown2

Clinical trials

7 shown

Rociletinib Genomic Landscape in Non-small Cell Lung Cancer (NSCLC)NCT02705339 · 2016-05-01

A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLCNCT02630186 · 2016-02-24

Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung CancerNCT02580708 · 2015-09-30

TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet ChemotherapyNCT02322281 · 2015-02-01

Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung CancerNCT02147990 · 2014-06-16

Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) PatientsNCT01526928 · 2012-03-27

Rociletinib (CO-1686) USA Expanded Access ProgramNCT02547675

NO_LONGER_AVAILABLE

Common conditions

Non-small Cell Lung Cancer6 Carcinoma, Non-Small-Cell Lung1 Locally Advanced or Metastatic Non Small Cell Lung Cancer1 Nonsmall Cell Lung Cancer1

Leading sponsors

Clovis Oncology, Inc. 6 Washington University School of Medicine 1

Trial status mix

TERMINATED5

NO_LONGER_AVAILABLE1

WITHDRAWN1

Phase mix

PHASE25

PHASE13

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.